NFKB1 and thyroid gland carcinoma: Hence, data from the literature demonstrate that the efficacy of NF-κB inhibition is not proven in all PDTC- and ATC-derived cell lines, neither in the absence nor in the presence of drugs affecting the other main signal pathways involved in aggressive thyroid carcinomas.